AZ D5180C00018 DESTINATION: A multicentre double blind randomized placebo controlled parallel group phase 3 safety extension study to evaluate safety & tolerability of Tezepelumab

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

AstraZeneca Pharmaceuticals, LP

Contributors

Que, Loretta Georgina Principal Investigator

Start/End

July 12, 2019 - October 31, 2023